Company Profile
Amicus Therapeutics Stock Price, News & Analysis
- Ticker:
- FOLD
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs
- Location:
- United States
Stock performance
14.49 USD (+0.21%)
Close
Last updated: April 24, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for FOLD.
Company overview
Business overview
Amicus Therapeutics is a rare-disease company focused on Fabry and Pompe disease through commercial therapies and pipeline work.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Amicus sits in specialty biopharma.
Business Model Characteristics
The company combines orphan-drug commercialization with a pipeline that can extend the rare-disease franchise.
Position Within the Biotechnology Landscape
Amicus occupies a durable rare-disease niche where commercial execution and label expansion matter more than broad pipeline breadth.
Future catalysts
Amicus's catalysts are Pombiliti plus Opfolda commercial uptake and continued Galafold execution in Fabry disease. The company is trying to prove that its rare-disease platform can keep compounding beyond a single product cycle.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amicus Therapeutics (FOLD)?
Amicus Therapeutics (FOLD) most recently closed at 14.49 USD, a +0.21% move versus the previous session.
What does Amicus Therapeutics do?
Amicus Therapeutics is a rare-disease company focused on Fabry and Pompe disease through commercial therapies and pipeline work.
On which exchange is FOLD stock listed?
Amicus Therapeutics (FOLD) is associated with NASDAQ, United States, Small Molecule Drugs.
What is Amicus?
Amicus's catalysts are Pombiliti plus Opfolda commercial uptake and continued Galafold execution in Fabry disease.
Which conditions is Amicus Therapeutics targeting with Amicus?
Amicus's catalysts are Pombiliti plus Opfolda commercial uptake and continued Galafold execution in Fabry disease.
How does Amicus Therapeutics describe recent progress with Amicus?
Amicus's catalysts are Pombiliti plus Opfolda commercial uptake and continued Galafold execution in Fabry disease.
What is Therapeutics?
Amicus Therapeutics is a rare-disease company focused on Fabry and Pompe disease through commercial therapies and pipeline work.
What should investors watch for with Therapeutics?
Amicus's catalysts are Pombiliti plus Opfolda commercial uptake and continued Galafold execution in Fabry disease. The company is trying to prove that its rare-disease platform can keep compounding beyond a single product cycle.